262 600

Cited 0 times in

Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy

 Jeongshim Lee  ;  Jee Suk Chang  ;  Mi Ryung Roh  ;  Minkyu Jung  ;  Choong-Kun Lee  ;  Byung Ho Oh  ;  Kee Yang Chung  ;  Woong Sub Koom  ;  Sang Joon Shin 
 CANCER RESEARCH AND TREATMENT, Vol.52(3) : 730-738, 2020-07 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Immune Checkpoint Inhibitors / therapeutic use* ; Male ; Melanoma / drug therapy ; Melanoma / mortality* ; Melanoma / pathology ; Middle Aged ; Patient Selection* ; Prognosis ; Republic of Korea ; Retrospective Studies ; Survival Rate ; Young Adult
Asia ; Immune checkpoint blocker ; Immunotherapy ; Melanoma
Purpose: We investigated the clinical efficacy of immune checkpoint blocker (ICB) therapy for metastatic or advanced melanoma in Korean patients. As well, we assessed whether the effects of ICBs can be enhanced by combination therapy with palliative radiotherapy (RT).

Materials and methods: We retrospectively reviewed the records of 127 patients with metastatic melanoma who received ICB with or without palliative RT between 2014 and 2018. The melanoma subtypes were classified as follows: chronic sun-damaged (CSD), acral, mucosal, and uveal. The primary endpoint was the objective response rate (ORR).

Results: The overall ORR was 15%, with 11 complete and eight partial responses. ORRs for CSD, acral/mucosal, and uveal melanomas were 50%, 16.5%, and 0%, respectively (p=0.009). In addition to the subtype, stage at treatment, total tumor burden at treatment, and ICB type were significantly associated with ORR (all p < 0.05). Palliative RT was administered in 44% of patients during the treatment, and it did not affect ORR. Clinical responders to ICB therapy exhibited significantly higher 1-year progression-free and overall survival rates than nonresponders.

Conclusion: ORR for ICB monotherapy in Korean patients with melanoma is relatively modest compared with that in Western patients because the non-CSD subtypes are predominant in the Korean population. Our findings regarding combination therapy with ICB provided a rationale for the initiation of our phase II study (NCT04017897).
Files in This Item:
T202002923.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Koom, Woong Sub(금웅섭) ORCID logo https://orcid.org/0000-0002-9435-7750
Roh, Mi Ryung(노미령) ORCID logo https://orcid.org/0000-0002-6285-2490
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Oh, Byung Ho(오병호) ORCID logo https://orcid.org/0000-0001-9575-5665
Lee, Choong-kun(이충근) ORCID logo https://orcid.org/0000-0001-5151-5096
Chang, Jee Suk(장지석) ORCID logo https://orcid.org/0000-0001-7685-3382
Chung, Kee Yang(정기양) ORCID logo https://orcid.org/0000-0003-3257-0297
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.